SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2184321

Cover Image

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2184321

Peptide-Based Gastrointestinal Disorders Therapeutics Market, By Drug, By Application, By Route of Administration, By Distribution Channel, By Geography

PUBLISHED:
PAGES: 257 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4500
PDF & Excel (Multi User License - Up to 7 Users)
USD 7000
PDF & Excel (Corporate User License)
USD 10000

Add to Cart

Peptide-Based Gastrointestinal Disorders Therapeutics Market is estimated to be valued at USD 5.79 Bn in 2026 and is expected to reach USD 9.80 Bn by 2033, growing at a compound annual growth rate (CAGR) of 7.8% from 2026 to 2033.

Report Coverage Report Details
Base Year: 2025 Market Size in 2026: USD 5.79 Bn
Historical Data for: 2020 to 2024 Forecast Period: 2026 to 2033
Forecast Period 2026 to 2033 CAGR: 7.80% 2033 Value Projection: USD 9.80 Bn

The market is witnessing steady growth mainly driven by the increasing prevalence of gastrointestinal disorders, rising adoption of peptide-based therapies, and continued development and commercialization of targeted treatments for conditions such as irritable bowel syndrome with constipation (IBS-C), chronic constipation, and short bowel syndrome.

Peptide-based gastrointestinal therapeutics include peptide and peptide-analog medicines designed to regulate gastrointestinal function, improve intestinal absorption, and manage chronic gastrointestinal symptoms. Key therapies covered in the market include linaclotide, teduglutide, and plecanatide, which are administered through oral and injectable routes depending on the indication and treatment requirement.

The market is increasingly benefiting from indication expansion and broader patient access to established peptide therapies. In November 2025, the U.S. FDA approved linaclotide for pediatric patients aged seven years and older with IBS-C, while in May 2026, its functional constipation indication was expanded to children aged two years and older. Development of long-acting peptide analogs for severe gastrointestinal conditions such as short bowel syndrome with intestinal failure is also broadening the therapeutic scope of the market.

Market Dynamics

The market is witnessing strong momentum owing to the growing burden of irritable bowel syndrome, chronic idiopathic constipation, functional constipation, and short bowel syndrome, together with increasing adoption of peptide-based treatment approaches. A 2026 systematic review and meta-analysis across 44 countries estimated the pooled prevalence of functional constipation at 12.14%, highlighting a substantial potential treatment population.

Growth is also being supported by strong commercialization of established therapies such as linaclotide and plecanatide. Linaclotide is expected to account for approximately 61.5% of the market in 2026, supported by its established use across IBS-C, chronic idiopathic constipation, and pediatric functional constipation. The irritable bowel syndrome segment is projected to account for approximately 43.5% of the market in 2026, reflecting the substantial disease burden and availability of targeted peptide treatments.

The development of next-generation and long-acting peptide analogs is further strengthening the market outlook. Companies are increasingly evaluating peptide therapies that may reduce dependence on parenteral nutrition and improve intestinal absorption in patients with short bowel syndrome. In June 2026, Ironwood Pharmaceuticals commenced the Phase III STARS-2 trial of apraglutide, a once-weekly synthetic GLP-2 analog for short bowel syndrome with intestinal failure.

Expansion of pediatric indications, improved prescription access, established retail pharmacy infrastructure, and continued commercialization across major markets are also contributing to market development. However, factors such as the high treatment cost of branded peptide therapeutics and limited availability of peptide-based gastrointestinal therapies in emerging markets may restrict broader adoption.

Key Features of the Study

  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the Peptide-Based Gastrointestinal Disorders Therapeutics Market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Ironwood Pharmaceuticals, Inc., NPS Pharmaceuticals, Inc., Synergy Pharmaceuticals Inc., Astellas Pharma Inc., Allergan plc., and Cipher Pharmaceuticals Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The Peptide-Based Gastrointestinal Disorders Therapeutics Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Peptide-Based Gastrointestinal Disorders Therapeutics Market

Market Segmentation

  • By Drug (Revenue, USD Bn, 2021-2033)
  • Linaclotide
  • Teduglutide
  • Plecanatide
  • By Application (Revenue, USD Bn, 2021-2033)
  • Irritable Bowel Syndrome
  • Chronic Constipation
  • Short Bowel Syndrome
  • Others
  • By Route of Administration (Revenue, USD Bn, 2021-2033)
  • Oral
  • Injectable
  • By Distribution Channel (Revenue, USD Bn, 2021-2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Region (Revenue, USD Bn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa
  • Key Players
  • Ironwood Pharmaceuticals, Inc.
  • NPS Pharmaceuticals, Inc.
  • Synergy Pharmaceuticals Inc.
  • Astellas Pharma Inc.
  • Allergan plc.
  • Cipher Pharmaceuticals Inc.
Product Code: CMI2028

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug
    • Market Snapshot, By Application
    • Market Snapshot, By Route of Administration
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Product Approval
  • Collaboration/Merge/Acquisition
  • Regulatory Landscape
  • PEST Analysis
  • Porter's Five Forces Analysis
  • Epidemiology
  • Robust Pipeline Analysis

4. Global Peptide-Based Gastrointestinal Disorders Therapeutics Market, By Drug, 2021 - 2033, (USD Billion)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022- 2033
    • Segment Trends
  • Linaclotide
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
  • Teduglutide
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
  • Plecanatide
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

5. Global Peptide-Based Gastrointestinal Disorders Therapeutics Market, By Application, 2021 - 2033, (USD Billion)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022- 2033
    • Segment Trends
  • Irritable Bowel Syndrome
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
  • Chronic Constipation
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
  • Short Bowel Syndrome
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

6. Global Peptide-Based Gastrointestinal Disorders Therapeutics Market, By Route of Administration, 2021 - 2033, (USD Billion)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022- 2033
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
  • Injectable
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

7. Global Peptide-Based Gastrointestinal Disorders Therapeutics Market, By Distribution Channel, 2021 - 2033, (USD Billion)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022- 2033
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

8. Global Peptide-Based Gastrointestinal Disorders Therapeutics Market, By Region, 2021 - 2033, (USD Billion)

  • Introduction
    • Market Share Analysis, By Region, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, For Regions, 2022-2033
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
      • North Africa
      • Central Africa
      • South Africa

9. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis
  • Company Profile
    • Ironwood Pharmaceuticals, Inc.
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • NPS Pharmaceuticals, Inc.
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • Synergy Pharmaceuticals Inc.
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • Astellas Pharma Inc.
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • Allergan plc.
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • Cipher Pharmaceuticals Inc.
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
  • Analyst Views

10. Section

  • References
  • Research Methodology
  • About Us
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!